Trial Profile
A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Hypophosphatasia (HPP) in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease
- 04 Aug 2016 Status changed from active, no longer recruiting to completed.
- 28 Aug 2015 New trial record